Victory Capital Management
IRWD icon

Victory Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Victory Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.77M Sell
658,457
-54,730
-8% -$211K ﹤0.01% 1544
2026
Q1 		$2.5M Buy
713,187
+695,145
+3,853% +$2.85M ﹤0.01% 1538
2025
Q4 		$60.8K Buy
18,042
+37
+0.2% +$96 ﹤0.01% 2314
2025
Q3 		$23.6K Sell
18,005
-614
-3% -$635 ﹤0.01% 2389
2025
Q2 		$13.4K Sell
18,619
-95
-0.5% -$75 ﹤0.01% 2465
2025
Q1 		$27.5K Sell
18,714
-194,578
-91% -$463K ﹤0.01% 2411
2024
Q4 		$945K Sell
213,292
-4,717
-2% -$19.1K ﹤0.01% 1836
2024
Q3 		$898K Sell
218,009
-4,564
-2% -$24.5K ﹤0.01% 1822
2024
Q2 		$1.45M Buy
222,573
+94,882
+74% +$671K ﹤0.01% 1547
2024
Q1 		$1.11M Sell
127,691
-4,096,892
-97% -$49.7M ﹤0.01% 1693
2023
Q4 		$48.3M Sell
4,224,583
-182,149
-4% -$1.8M 0.05% 448
2023
Q3 		$42.4M Buy
4,406,732
+668,694
+18% +$6.55M 0.05% 460
2023
Q2 		$39.8M Buy
3,738,038
+707,706
+23% +$7.61M 0.04% 500
2023
Q1 		$31.9M Buy
3,030,332
+127,656
+4% +$1.43M 0.04% 609
2022
Q4 		$36M Buy
2,902,676
+845
+0% +$9.59K 0.04% 574
2022
Q3 		$30.1M Buy
2,901,831
+2,738,889
+1,681% +$31.1M 0.04% 645
2022
Q2 		$1.88M Sell
162,942
-12,046
-7% -$142K ﹤0.01% 1483
2022
Q1 		$2.1M Buy
174,988
+17,017
+11% +$195K ﹤0.01% 1484
2021
Q4 		$1.84M Buy
157,971
+81,084
+105% +$995K ﹤0.01% 1581
2021
Q3 		$1M Buy
76,887
+25,378
+49% +$328K ﹤0.01% 1863
2021
Q2 		$663K Buy
51,509
+2,881
+6% +$33K ﹤0.01% 2059
2021
Q1 		$544K Buy
48,628
+6,625
+16% +$70K ﹤0.01% 2165
2020
Q4 		$478K Buy
42,003
+9,298
+28% +$102K ﹤0.01% 2104
2020
Q3 		$294K Buy
32,705
+12,607
+63% +$125K ﹤0.01% 2169
2020
Q2 		$207K Sell
20,098
-182
-0.9% -$1.86K ﹤0.01% 2291
2020
Q1 		$205K Sell
20,280
-5,812
-22% -$68.3K ﹤0.01% 2143
2019
Q4 		$347K Buy
26,092
+4,516
+21% +$49.8K ﹤0.01% 2157
2019
Q3 		$185K Buy
+21,576
New +$210K ﹤0.01% 2243

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Victory Capital Management's IRWD Position: Q2 2026 in Review

Victory Capital Management reduced its Ironwood Pharmaceuticals (IRWD) stake by 7.7% in Q2 2026, selling an estimated $211K and leaving 658,457 shares worth $2.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1544.

Victory Capital Management first reported a position in IRWD in Q3 2019 and has held it in 28 quarters since. The position peaked at $48.3M in Q4 2023. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Victory Capital Management held 658,457 shares of Ironwood Pharmaceuticals worth $2.77M as of Q2 2026.
  • Victory Capital Management sold 54,730 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $211K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1544 holding.
  • Victory Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2019 and has held it in 28 quarters since.
  • Victory Capital Management's Ironwood Pharmaceuticals position peaked at $48.3M in Q4 2023.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.